

**Basics**

Nationality British  
GMC Number 3137956  
Address Division of Digestive Diseases, Imperial College, Norfolk Place, London, W2 1NY  
Telephone 0207 886 1903  
Email [m.thursz@imperial.ac.uk](mailto:m.thursz@imperial.ac.uk)

**Education and Qualifications**

1981-1986 King's College School of Medicine & Dentistry, London  
June 1986 MB,BS University of London  
June 1989 MRCP  
March 1997 MD University of London  
July 2004 FRCP

**Current and Previous Appointments**

01.10.17 – present Director Imperial Biomedical Research Centre  
01.10.17 – present Trust Research Director Imperial College Healthcare NHS Trust  
01.08.15 – present Head of Division of Digestive Diseases, Imperial College London  
01.04.11 – present Head of Section Gastroenterology & Hepatology, Imperial College London  
01.04.10 – present Clinical Lead Hepatology, Imperial College Healthcare  
07.07.06 – present Professor of Hepatology, Imperial College.  
01.05.09 – 30.04.13 Secretary General European Association for Study of the Liver  
01.05.09 – 30.04.11 Vice-Secretary European Association for Study of the Liver  
01.10.02 – 30.09.05 Secretary British Association for Study of the Liver  
01.04.99 – 30.03.01 Clinical Lead in Gastroenterology, St Mary's Hospital  
01.05.97 – 07.07.06 Senior Lecturer & Reader in Medicine, Imperial College.  
01.05.97 – present Honorary Consultant Gastroenterology & Hepatology, Imperial Healthcare NHS Trust  
1.5.95 - 30.4.97 Lecturer, Department of Medicine, Imperial College School of Medicine

**Advisory & Consultancy Roles**

- Hepatitis C Coalition – Chair
- WHO Roster of Experts – Viral Hepatitis
- WHO Guidelines Development Group: Hepatitis B
- United European Gastroenterology Federation - General Assembly Member

**Current Grants and Fellowships**

- MRC Stratified Medicine: Minimising Mortality from Alcoholic Hepatitis 2018 – 2023. £5.6M
- National Institute for Medical Research-EME Trial grant. Nucleoside Analogue Withdrawal in HBeAg negative patients with chronic hepatitis B (NUC-B). £2.4M 2016-2021.
- MRC Clinical Research Training Fellowship Dr Stephen Atkinson: "Genomic and metabonomic markers in alcoholic hepatitis" 2015 - 2018
- MRC Clinical Research Fellowship Dr Shevanthi Nayagam: "Mathematical models to predict the outcome of public health interventions to control hepatitis B virus". 2013-2016
- Wellcome Trust Clinical Research Fellowship Dr Nikhil Vergis: "Monocyte dysfunction in alcoholic hepatitis" 2012 – 2015

- EC FP7 Grant: Participant “Dengue Framework for Resisting Epidemics in Europe (Denfree)”. €210,000 of €3M Nov 2011 – Oct 2016
- EC FP7 Grant: Coordinator “Prevention of Liver Fibrosis and Cancer in Africa (Prolifica)”. €3M March 2011 – Feb 2016.
- EC FP7 Grant: Participant “Host and viral factors in acute hepatitis C (HepAcute)”. €300,000 of €3M March 2010 – Feb 2013.
- NHS Health Technology Assessment – Clinical Trials Grant: “Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH)” . £2.5M. July 2009 – June 2013
- MRC Experimental Medicine: “Warfarin Anticoagulation for Liver Fibrosis in patients Transplanted for Hepatitis C Virus infection (WAFT-C)”. £720,000 July 2008 – June 2013.

**Publications (Selected)**

1. Vergis N, Atkinson S, .. Patch D, Ryder S, Wright M, Thursz M. Infection in severe alcoholic hepatitis: risk stratification, association with prednisolone therapy and impact on survival. *Gastroenterology* 2017 In Press
2. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, Hallett TB. Requirements for global elimination of hepatitis B: a modelling study. *Lancet Infect Dis*. 2016 Sep 13. pii: S1473-3099(16)30204-3. doi: 10.1016/S1473-3099(16)30204-3. [Epub ahead of print] PubMed PMID: 27638356.
3. Nayagam S, Conteh L, Sicuri E, Shimakawa Y, Suso P, Tamba S, Njie R, Njai H, Lemoine M, Hallett TB, Thursz M. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. *Lancet Glob Health*. 2016 Aug;4(8):e568-78. doi: 10.1016/S2214-109X(16)30101-2. PubMed PMID: 27443782.
4. Lemoine M, Shimakawa Y, Njie R, ..Mendy M, Thursz MR; PROLIFICA investigators.. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. *Lancet Glob Health*. 2016 Aug;4(8):e559-67.
5. Thursz M, Morgan TR. Treatment of Severe Alcoholic Hepatitis. *Gastroenterology*. 2016 Mar 3. pii: S0016-5085(16)00295-X. doi:10.1053/j.gastro.2016.02.074. [Epub ahead of print] PubMed PMID: 26948886.
6. Vergis N, Khamri W, .. Wendon JA, Antoniadou CG, ThurszMR. Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. *Gut*. 2016 Feb 9. pii:gutjnl-2015-310378. doi: 10.1136/gutjnl-2015-310378. [Epub ahead of print] PubMed PMID: 26860769.
7. Blackmore LJ, Ryan JM, Huang X, Hussain M, Triantafyllou E, Vergis N, Vijay GM, Antoniadou CG, Thursz MR, Jassem W, Vergani D, Shawcross DL, Ma Y. Acute alcoholic hepatitis and cellular Th1 immune responses to alcohol dehydrogenase. *Lancet*. 2015 Feb 26;385 Suppl 1:S22
8. Shimakawa Y, Lemoine M, .. Thursz M, Mendy M. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. *Gut*. 2015 Jul 16. pii: gutjnl-2015-309892. doi: 10.1136/gutjnl-2015-309892.
9. Singh S, Murad MH, Chandar AK, Bongiorno CM, Singal AK, Atkinson SR, Thursz MR, Loomba R, Shah VH. Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. *Gastroenterology*. 2015 Oct;149(4):958-970
10. Thursz MR, Richardson P, Allison M et al. Prednisolone or Pentoxifylline for Alcoholic Hepatitis. *N Engl J Med*. 2015 Apr 23;372(17):1619-28.
11. Bernsmeier C, Pop OT, ... Adams DH, Quaglia A, Thursz MR, Wendon J, Antoniadou CG. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. *Gastroenterology*. 2015 Mar;148(3):603-615.e14
12. Antoniadou CG, ... Wendon J, Thursz M. Secretory leukocyte protease inhibitor: a pivotal mediator of anti-inflammatory responses in acetaminophen-induced acute liver failure. *Hepatology*. 2014 Apr;59(4):1564-76.
13. European Association for the Study of Liver. EASL clinical practice guidelines: management of alcoholic liver disease. *J Hepatol*. 2012 Aug;57(2):399-420
14. Antoniadou CG, Quaglia A, Taams LS, Mitry RR, Hussain M, Abeles R, Possamai LA, Bruce M, McPhail M, Starling C, Wagner B, Barnardo A, Pomplun S, Auzinger G, Bernal W, Heaton N, Vergani D, Thursz MR, Wendon J. Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans. *Hepatology*. 2012 Aug;56(2):735-46.